NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
(Total Views: 234)
Posted On: 08/24/2018 8:23:06 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human Clinical Study Confirms Significant Delivery, Bioavailability Results
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is pleased with recent significant results from a new human clinical study to evaluate its DehydraTECH™ powered TurboCBD™ and cannabidiol (CBD) fortified hemp oil capsules (http://nnw.fm/T7d2E). An article discussing this reads, “Results corroborate and confirm earlier in vitro and in vivo studies that evaluated DehydraTECH’s platform and measured higher levels of drug delivery achieved quicker than controls with matching CBD amounts. LXRP said that it believes nearly identical bioavailability enhancement results would be shown if the cannabinoid was THC instead of CBD.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is pleased with recent significant results from a new human clinical study to evaluate its DehydraTECH™ powered TurboCBD™ and cannabidiol (CBD) fortified hemp oil capsules (http://nnw.fm/T7d2E). An article discussing this reads, “Results corroborate and confirm earlier in vitro and in vivo studies that evaluated DehydraTECH’s platform and measured higher levels of drug delivery achieved quicker than controls with matching CBD amounts. LXRP said that it believes nearly identical bioavailability enhancement results would be shown if the cannabinoid was THC instead of CBD.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼